Envudeucitinib
Asset
Inhibits TYK2 to reduce inflammatory cytokine signaling.
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Psoriasis
Phase 3, globenewswire.com, 9 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets1
- Competitors7
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.